Hana Biosciences (HNAB) Acquires Rights to Develop and Commercialize Menadione
Hana Biosciences (NASDAQ: HNAB) announced that it has acquired exclusive rights to develop and commercialize Menadione, a preclinical product candidate for the prevention and treatment of skin rash associated with the use of epidermal growth factor receptor (EGFR) inhibitors in the treatment of certain cancers.
The activity of Menadione was discovered in the laboratory of Roman Perez-Soler, M.D., Chief of the Division of Oncology in the Department of Medicine at the Albert Einstein College of Medicine in New York.
Based on numerous clinical studies, an estimated 75 percent of cancer patients receiving treatment with EGFR inhibitors develop significant skin toxicities presenting as acne-like rash on the face and upper body.
In vivo studies have suggested that topically-applied menadione may restore EGFR signaling specifically in the skin of patients treated systemically with EGFR inhibitors. Currently prescribed EGFR inhibitors include Erbitux; ImClone Systems (Nasdaq: IMCL) and Bristol-Myers Squibb (NYSE: BMY), Tarceva; OSI Pharmaceuticals (Nasdaq: OSIP) and Genentech (NYSE: DNA), and Vectibix; Amgen (Nasdaq: AMGN).
The activity of Menadione was discovered in the laboratory of Roman Perez-Soler, M.D., Chief of the Division of Oncology in the Department of Medicine at the Albert Einstein College of Medicine in New York.
Based on numerous clinical studies, an estimated 75 percent of cancer patients receiving treatment with EGFR inhibitors develop significant skin toxicities presenting as acne-like rash on the face and upper body.
In vivo studies have suggested that topically-applied menadione may restore EGFR signaling specifically in the skin of patients treated systemically with EGFR inhibitors. Currently prescribed EGFR inhibitors include Erbitux; ImClone Systems (Nasdaq: IMCL) and Bristol-Myers Squibb (NYSE: BMY), Tarceva; OSI Pharmaceuticals (Nasdaq: OSIP) and Genentech (NYSE: DNA), and Vectibix; Amgen (Nasdaq: AMGN).
You May Also Be Interested In
- Pfizer (PFE) Axitinib Gets Positive Opinion from CHMP EMA
- Boehringer Ingelheim, Lilly (LLY) Say Linagliptin Showed Significant Improvement in HbA1c in Phase 3
- Celldex Therapeutics (CLDX) Announces 'High Response' CDX-011 Trial Data
Create E-mail Alert Related Categories
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
